Ampa Accelerates Rollout of Portable Neuromodulation Platform with Oversubscribed Financing
Summary
Ampa announced an oversubscribed financing round that brings total funding to more than $25 million, led by Morningside Ventures, Trimera Capital, Neta Foundation, Jake Collective, and technology investor Tim Ferriss. Ampa has developed a portable transcranial magnetic stimulation device costing $3,000 per month that fits in a car trunk and can be operated after a few hours of training, dramatically lowering barriers to offering TMS therapy. The FDA-cleared Ampa One system is already used by clinics in more than 30 states and has secured regulatory approval in Israel.
Why it matters
Ampa's approach addresses the fundamental accessibility problem in TMS therapy, where traditional equipment costs hundreds of thousands of dollars and requires dedicated clinic space. By making TMS portable and affordable, Ampa could dramatically expand access to a proven depression treatment for patients who have not responded to medications. Tim Ferriss's public endorsement brings mainstream attention to neurotechnology and signals that portable neuromodulation is reaching an inflection point in commercial adoption.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial